Exploration of biomarkers for early recognition of FVIII inhibitor development in previously untreated severe hemophilia A patients: Hemophilia Inhibitor PUP Study and beyond

被引：0
|
作者：
Hofbauer, C. J. [1 ]
Male, C. [2 ]
Brown, D. [3 ]
Santagostino, E. [4 ]
Oldenburg, J. [5 ]
Scheiflinger, F. [1 ]
Reipert, B. M. [1 ]
机构：
[1] Baxter BioSci, Vienna, Austria
[2] Med Univ Vienna, Vienna, Austria
[3] Univ Texas Houston, Houston, TX USA
[4] Univ Milan, Milan, Italy
[5] Univ Clin Bonn, Bonn, Germany
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2013年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：133 / 133
页数：1
相关论文
共 50 条
  • [31] Incidence of factor VIII inhibitor in Korean previously untreated hemophilia A patients
    Yoo, Ki Young
    Park, Young Shil
    Kim, Ji Yoon
    HAEMOPHILIA, 2018, 24 : 28 - 28
  • [32] Inhibitor incidence in previously untreated patients (PUPs) with severe hemophilia A receiving recombinant factor (rFVIII)
    Rothschild, C
    Laurian, Y
    Satre, EP
    BorelDerlon, A
    Chambost, H
    Moreau, P
    Goudemand, J
    Parquet, A
    Vicariot, M
    Beurrier, P
    Claeyssens, S
    Durin, A
    Faradji, A
    Fressinaud, E
    Gaillard, S
    Guerin, V
    Guerois, C
    Pernod, G
    Peynet, J
    Pouzol, P
    Schved, JF
    Gazengel, C
    THROMBOSIS AND HAEMOSTASIS, 1997, : P2654 - P2654
  • [33] Determinants of inhibitor development in previously treated hemophilia A patients
    Iorio, A.
    Barbara, A.
    Castaman, G.
    Fischer, K.
    Gilman, E.
    Goudemand, J.
    Kavakli, K.
    Kubicek-Hofmann, C.
    Lambert, T.
    Lissitchkov, T.
    Makris, M.
    Matthew, P.
    Castelano, M. E. M.
    Ozdemir, N.
    Parra, R.
    Peerlinck, K.
    Rivolta, G.
    Romanov, V
    Roussel-Robert, V
    Tagliaferri, A.
    Windyga, J.
    Zanon, E.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 149 - 149
  • [34] Latest results from the PUP-GCP clinical trial: a low inhibitor rate in previously untreated patients with severe hemophilia A treated with octanate
    Klukowska, A.
    Jansen, M.
    Komrska, V.
    Laguna, P.
    Vdovin, V.
    Knaub, S.
    HAEMOPHILIA, 2014, 20 : 19 - 20
  • [35] Latest results from the PUP-GCP clinical trial: a low inhibitor rate in previously untreated patients with severe hemophilia A treated with octanate
    Klukowska, A.
    Jansen, M.
    Komrska, V
    Laguna, P.
    Vdovin, V.
    Knaub, S.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2014, 12 : 38 - 38
  • [36] Latest Results From The PUP-GCP Clinical Trial: A Low Inhibitor Rate In Previously Untreated Patients With Severe Hemophilia A Treated With Octanate
    Klukowska, Anna
    Jansen, Martina
    Komrska, Vladimir
    Laguna, Pawel
    Vdovin, Vladimir
    Knaub, Sigurd
    BLOOD, 2013, 122 (21)
  • [37] Latest results from The PUP-GCP clinical trial: A low inhibitor rate in previously untreated patients with severe hemophilia A treated with Octanate
    Klukowska, Anna
    Knaub, Sigurd
    Komrska, Vladimir
    Laguna, Pawel
    Vdovin, Vladimir
    Jansen, Martina
    HAEMOPHILIA, 2014, 20 : 17 - 17
  • [38] Risk of Bleeding and Inhibitor Development After Circumcision of Previously Untreated or Minimally Treated Severe Hemophilia A Children
    Elalfy, Mohsen S.
    Elbarbary, Nancy S.
    Eldebeiky, Mohamed S.
    El Danasoury, Azza S.
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2012, 29 (05) : 485 - 493
  • [39] Recombinant factor IX (rFIX) in the treatment of previously untreated patients (PUP) with severe or moderately severe hemophilia
    Shapiro, A
    Abshire, T
    Kisker, T
    Peerlinck, K
    Fernands, A
    Gencarella, N
    BLOOD, 1999, 94 (10) : 238A - 238A
  • [40] Risk of bleeding and inhibitor development after circumcision of Previously Untreated (PUPs) or Minimally Treated (MTPs) severe hemophilia A patients
    Elalfy, M.
    Elbarbary, N.
    Eldebeiky, M.
    El Danasoury, A.
    HAEMOPHILIA, 2012, 18 : 89 - 89
12345